An Open-Label, Phase 1, Randomized, Two-Treatment, Two-Period, Two-Way Crossover, Relative Bioavailability Study Of A Capsule And A Tablet Formulation Of ARQ 197 In Subjects With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Tivantinib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- 07 Jun 2011 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
- 07 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Nov 2010 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov